{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T13:46:55Z","timestamp":1793713615386,"version":"4.6.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T00:00:00Z","timestamp":1635379200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.jtho.2021.10.010","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T18:33:37Z","timestamp":1634927617000},"page":"200-213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":330,"title":["The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9722-2483","authenticated-orcid":false,"given":"Alexander","family":"Marx","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K.C.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Chalabreysse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Dacic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Detterbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"French","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason L.","family":"Hornick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Inagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepali","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander J.","family":"Lazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirella","family":"Marino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith M.","family":"Marom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre L.","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew G.","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Nonaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro G.","family":"Papotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Porubsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynette M.","family":"Sholl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Tateyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Thomas de Montpr\u00e9ville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Travis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Rajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja C.","family":"Roden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Str\u00f6bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2021.10.010_bib1","article-title":"Thoracic tumours","volume":"5","year":"2021"},{"key":"10.1016\/j.jtho.2021.10.010_bib2","article-title":"WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart","volume":"7","author":"Travis","year":"2015"},{"key":"10.1016\/j.jtho.2021.10.010_bib3","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1097\/JTO.0000000000000269","article-title":"Development of the international thymic malignancy interest group international database: an unprecedented resource for the study of a rare group of tumors","volume":"9","author":"Huang","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2021.10.010_bib4","series-title":"TNM Classification of Malignant Tumours","year":"2017"},{"issue":"suppl 2","key":"10.1016\/j.jtho.2021.10.010_bib5","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1097\/JTO.0000000000000290","article-title":"The IASLC\/ITMIG Thymic Epithelial Tumors Staging Project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors","volume":"9","author":"Detterbeck","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2021.10.010_bib6","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jtho.2019.11.013","article-title":"The International Association for the Study of Lung Cancer thymic tumors staging project: the impact of the eighth edition of the Union for International Cancer Control and American Joint Committee on Cancer TNM stage classification of thymic tumors","volume":"15","author":"Ruffini","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2021.10.010_bib7","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ccell.2018.01.003","article-title":"The integrated genomic landscape of thymic epithelial tumors","volume":"33","author":"Radovich","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2021.10.010_bib8","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/ng.3016","article-title":"A\u00a0specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors","volume":"46","author":"Petrini","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2021.10.010_bib9","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.3389\/fimmu.2019.02965","article-title":"The intriguing history of cancer immunotherapy","volume":"10","author":"Dobosz","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtho.2021.10.010_bib10","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1097\/PAS.0000000000000653","article-title":"Comprehensive immunohistochemical study of programmed cell death ligand 1 (PD-L1): analysis in 5536 cases revealed consistent expression in trophoblastic tumors","volume":"40","author":"Inaguma","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2021.10.010_bib11","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/JTO.0000000000000429","article-title":"Diffuse high intensity PD-L1 staining in thymic epithelial tumors","volume":"10","author":"Padda","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2021.10.010_bib12","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s40425-019-0723-9","article-title":"Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (avelumab) treatment in advanced thymoma","volume":"7","author":"Rajan","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jtho.2021.10.010_bib13","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","volume":"37","author":"Cho","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2021.10.010_bib14","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2021.10.010_bib15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.21037\/med.2019.08.02","article-title":"Immune checkpoint inhibitors for treatment of thymic epithelial tumors: how to maximize benefit and optimize risk?","volume":"3","author":"Zhao","year":"2019","journal-title":"Mediastinum"},{"key":"10.1016\/j.jtho.2021.10.010_bib16","article-title":"Soft tissue and bone tumours","volume":"3","year":"2020"},{"key":"10.1016\/j.jtho.2021.10.010_bib17","volume":"8","year":"2016"},{"key":"10.1016\/j.jtho.2021.10.010_bib19","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.3390\/cancers12082032","article-title":"Primary driver mutations in GTF2I specific to the development of thymomas","volume":"12","author":"Higuchi","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.jtho.2021.10.010_bib20","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41379-019-0382-x","article-title":"Metaplastic thymoma: a distinctive thymic neoplasm characterized by YAP1-MAML2 gene fusions","volume":"33","author":"Vivero","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2021.10.010_bib21","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1200\/PO.19.00288","article-title":"Pan-Cancer landscape analysis reveals recurrent KMT2A-MAML2 gene fusion in aggressive histologic subtypes of thymoma","volume":"4","author":"Massoth","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2021.10.010_bib22","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s12253-016-0144-8","article-title":"Molecular profiling of thymoma and thymic carcinoma: genetic differences and potential novel therapeutic targets","volume":"23","author":"Enkner","year":"2017","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.jtho.2021.10.010_bib23","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/bjc.2015.425","article-title":"A\u00a0large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomas","volume":"114","author":"Radovich","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2021.10.010_bib24","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1200\/JCO.2017.74.4078","article-title":"Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy","volume":"36","author":"Zucali","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2021.10.010_bib25","doi-asserted-by":"crossref","first-page":"664","DOI":"10.3389\/fimmu.2020.00664","article-title":"Thymoma associated myasthenia gravis (TAMG): differential expression of functional pathways in relation to MG status in different thymoma histotypes","volume":"11","author":"Yamada","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtho.2021.10.010_bib26","first-page":"351","article-title":"Thymic carcinoma: introduction","volume":"5","author":"Chan","year":"2021"},{"key":"10.1016\/j.jtho.2021.10.010_bib27","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/modpathol.2012.40","article-title":"Micronodular thymic carcinoma with lymphoid hyperplasia: a clinicopathological and immunohistochemical study of five cases","volume":"25","author":"Weissferdt","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2021.10.010_bib28","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/his.13890","article-title":"EWSR1 translocation in primary hyalinising clear cell carcinoma of the thymus","volume":"75","author":"Porubsky","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.jtho.2021.10.010_bib29","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00428-019-02644-3","article-title":"Potentially actionable FGFR2 high-level amplification in thymic sebaceous carcinoma","volume":"476","author":"Porubsky","year":"2020","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jtho.2021.10.010_bib30","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/PAS.0000000000000359","article-title":"Adenocarcinoma of the thymus, enteric type: report of 2 cases, and proposal for a novel subtype of thymic carcinoma","volume":"39","author":"Moser","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2021.10.010_bib31","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/annonc\/mdw686","article-title":"Complex chromosomal rearrangements by single catastrophic pathogenesis in NUT midline carcinoma","volume":"28","author":"Lee","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2021.10.010_bib32","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2021.10.010_bib33","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1470-2045(20)30162-5","article-title":"Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial","volume":"21","author":"Sato","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2021.10.010_bib34","doi-asserted-by":"crossref","first-page":"6993","DOI":"10.18632\/oncotarget.24075","article-title":"A\u00a0comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma","volume":"9","author":"Sakane","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2021.10.010_bib35","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3892\/ol.2021.12744","article-title":"GAD1 expression and its methylation as indicators of malignant behavior in thymic epithelial tumors","volume":"21","author":"Soejima","year":"2021","journal-title":"Oncol Lett"},{"key":"10.1016\/j.jtho.2021.10.010_bib36","first-page":"1003","article-title":"A\u00a0tuft cell-like signature is highly prevalent in thymic squamous cell carcinoma and delineates new molecular subsets among the major lung cancer histotypes","volume":"16","author":"Yamada","year":"2021","journal-title":"J\u00a0Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"10.1016\/j.jtho.2021.10.010_bib37","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.jtho.2016.04.013","article-title":"PI3K as a potential therapeutic target in thymic epithelial tumors","volume":"11","author":"Alberobello","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2021.10.010_bib38","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/labinvest.2012.115","article-title":"Establishment and characterization of a novel cell line derived from human thymoma AB tumor","volume":"92","author":"G\u00f6kmen-Polar","year":"2012","journal-title":"Lab Investig"},{"key":"10.1016\/j.jtho.2021.10.010_bib39","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/ijc.23335","article-title":"Establishment, characterization and drug sensitivity testing in primary cultures of human thymoma and thymic carcinoma","volume":"122","author":"Ehemann","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtho.2021.10.010_bib40","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/01.pas.0000149690.75462.29","article-title":"Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients","volume":"29","author":"Pelosi","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2021.10.010_bib41","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1038\/s41379-018-0110-y","article-title":"A\u00a0common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal","volume":"31","author":"Rindi","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2021.10.010_bib42","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.jtho.2019.04.015","article-title":"Molecular classification of neuroendocrine tumors of the thymus","volume":"14","author":"Dinter","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2021.10.010_bib43","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/gcc.22183","article-title":"Tumor genetics and survival of thymic neuroendocrine neoplasms: a multi-institutional clinicopathologic study","volume":"53","author":"Str\u00f6bel","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.jtho.2021.10.010_bib44","first-page":"23","article-title":"Germ cell tumors from a developmental perspective: cells of origin, pathogenesis, and molecular biology (emerging pattern)","volume":"201","author":"Oosterhuis","year":"2017"},{"key":"10.1016\/j.jtho.2021.10.010_bib45","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1097\/PAS.0000000000001164","article-title":"A\u00a0clinicopathologic and molecular analysis of 34 mediastinal germ cell tumors suggesting different modes of teratoma development","volume":"42","author":"Kao","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2021.10.010_bib46","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.pathol.2018.10.002","article-title":"Analysis of chromosome 12p over-representation and clinicopathological features in mediastinal teratomas","volume":"51","author":"Lee","year":"2019","journal-title":"Pathology"},{"key":"10.1016\/j.jtho.2021.10.010_bib47","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jtho.2019.10.023","article-title":"SMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas","volume":"15","author":"Rekhtman","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2021.10.010_bib48","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/ng.3399","article-title":"SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas","volume":"47","author":"Le Loarer","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2021.10.010_bib49","doi-asserted-by":"crossref","unstructured":"Agaimy A, Haller F, Renner A, Niedermeyer J, Hartmann A, French CA. Misleading germ cell phenotype in pulmonary NUT carcinoma harboring the ZNF532-NUTM1 fusion [e-pub ahead of print]. Am J Surg Pathol. https:\/\/doi.org\/10.1097\/PAS.0000000000001774. Accessed July 8, 2021.","DOI":"10.1097\/PAS.0000000000001774"},{"key":"10.1016\/j.jtho.2021.10.010_bib50","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1097\/PAS.0b013e318198d666","article-title":"Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody","volume":"33","author":"Haack","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2021.10.010_bib51","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/s41379-021-00782-1","article-title":"Nuclear expression of DDIT3 distinguishes high-grade myxoid liposarcoma from other round cell sarcomas","volume":"34","author":"Baranov","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2021.10.010_bib52","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/PAS.0000000000001564","article-title":"DDIT3 immunohistochemistry is a useful tool for the diagnosis of myxoid liposarcoma","volume":"45","author":"Scapa","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2021.10.010_bib53","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ng.2509","article-title":"Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing","volume":"45","author":"Robinson","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2021.10.010_bib54","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1038\/modpathol.2017.54","article-title":"Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model","volume":"30","author":"Demicco","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2021.10.010_bib55","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/modpathol.2012.83","article-title":"Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model","volume":"25","author":"Demicco","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2021.10.010_bib56","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1097\/PAS.0000000000001447","article-title":"A\u00a0novel SS18-SSX fusion-specific antibody for the diagnosis of synovial sarcoma","volume":"44","author":"Baranov","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2021.10.010_bib57","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/PAS.0000000000001628","article-title":"The SS18-SSX antibody has perfect specificity for the SS18-SSX fusion protein: a validation study of 609 neoplasms including 2 unclassified tumors with SS18-non-SSX fusions","volume":"45","author":"Perret","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2021.10.010_bib58","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1542\/peds.2014-3673","article-title":"Vascular anomalies classification: recommendations from the International Society for the study of vascular anomalies","volume":"136","author":"Wassef","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.jtho.2021.10.010_bib59","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/nature14980","article-title":"Telomerase activation by genomic rearrangements in high-risk neuroblastoma","volume":"526","author":"Peifer","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2021.10.010_bib60","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/pin.13103","article-title":"Expression of cancer testis antigens in thymic epithelial tumors","volume":"71","author":"Sakane","year":"2021","journal-title":"Pathol Int"},{"key":"10.1016\/j.jtho.2021.10.010_bib61","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1101\/gad.314815.118","article-title":"POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer","volume":"32","author":"Huang","year":"2018","journal-title":"Genes Dev"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086421032585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086421032585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:48:15Z","timestamp":1761562095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086421032585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S1556086421032585"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2021.10.010","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2021.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}